TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01728948

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: treatment (including dose, duration, modification) decided by the investigator
Study: NCT03732690

Intervention type: OTHER
Group type: OTHER
Intervention: Diet HP
Description: 2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet LP
Description: 2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
Study: NCT02591849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperglycemic clamp

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycemic clamp
Study: NCT03294473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - Autodialers
Description: Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - Texting
Description: Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
Study: NCT02969226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS \>0 and =\< 8 cm H2O with PEEP\>0 and =\< 5 cm H2O

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
Study: NCT03294473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R/R - mailed postcard
Description: Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
Study: NCT00130273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managed problem solving
Description: Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
Study: NCT02969226

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
Study: NCT01604798

Intervention type: OTHER
Intervention: Serum proteomics
Description: magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry

Intervention type: OTHER
Intervention: Serum proteomics
Description: magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
Study: NCT04509232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Group A~* Excavation of soft carious dentin will be done to minimize the staining.~* The selected teeth should be cleaned, dried and isolated. Vaselline should be applied to surrounding soft tissues to avoid their staining.-~* 38% Silver diamine fluoride will be applied to carious lesions by microbrush~* Apply gentle flow of air until medicament is dry, Try to keep isolated for three minutes,remove excess SDF with cotton pellet to decrease systemic absorption.~After silver diamine fluoride application Assessement of parental acceptance to staining will be done though a 5 point likert scale For anterior and posterior teeth separately .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride and glass ionomer
Description: * 38% Silver diamine fluoride will be applied by the same protocol as in group A Then Glass Ionomer restoration is applied~* Parental acceptance to staining will be assessed thought 5 point likert scale after application of SDF and once more after application of Glass Ionomer restoration.
Study: NCT01881737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs.
Study: NCT04045145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crinecerfont
Description: Crinecerfont administered orally for 14 consecutive days.
Study: NCT02920047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Treatment B
Study: NCT00130273

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard of care for 12 months.
Study: NCT01361334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg QD p.o.
Study: NCT00929019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells electroporated with mRNA
Description: Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
Study: NCT03675724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Flavonoid Family

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT02338921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg qd per oral during 24months~compared with other treatment groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg qd per oral during 24months~compared with other treatment groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobeglitazone
Description: 0.5mg qd per oral during 24months~compared with other treatment groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepirde

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepirde

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepirde

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT05868018

Intervention type: BEHAVIORAL
Intervention: Education
Description: This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
Study: NCT02338921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01658488

Intervention type: OTHER
Group type: OTHER
Intervention: Non-fortified rice
Description: Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.

Intervention type: OTHER
Group type: OTHER
Intervention: Iron-fortified Rice
Description: Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
Study: NCT03613584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Von Willebrand Factor
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
Study: NCT02692235

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnitine
Description: 1500 mg/d l-carnitine-l-tartrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: isonitrogenous
Study: NCT03177564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective ventilation 1
Description: Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protective ventilation 2
Description: Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Driving Pressure Limited Ventilation
Description: Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
Study: NCT05436626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early BDI reconstruction without abdominal sepsis control
Description: BDI reconstruction within 6 weeks after the injury without abdominal sepsis control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early BDI reconstruction with abdominal sepsis control
Description: BDI reconstruction within 6 weeks after the injury with abdominal sepsis control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed reconstruction
Description: BDI reconstruction after 6 weeks after the injury
Study: NCT01828437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine plus prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study: NCT02725996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: Adjuvant adoptive immune therapy using NK cell 4 times

Intervention type: OTHER
Group type: OTHER
Intervention: Curative therapy
Description: Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curative therapy
Description: Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
Study: NCT02407496

Intervention type: OTHER
Intervention: Behavioral assessment and NAT EEG tests
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.

Intervention type: OTHER
Intervention: Behavioral assessment and NAT EEG tests
Description: Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
Study: NCT03447444

Intervention type: OTHER
Group type: OTHER
Intervention: music and physical activity
Description: This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
Study: NCT00844870

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stabilization training
Description: training of arm function with the trunk stabilized

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auditory training group
Description: response to an auditory signal
Study: NCT05868018

Intervention type: BEHAVIORAL
Intervention: Education
Description: This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.

Intervention type: BEHAVIORAL
Intervention: Education
Description: This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.

Intervention type: BEHAVIORAL
Intervention: Education
Description: This was an observational study of changes in evidence based confidence and behavior across 4 physical therapy programs. Students received their typical physical therapy education and we measured changes in evidence based practice confidence and behaviors across programs throughout the curriculum.
Study: NCT03937700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPWalker Robotic Exoskeleton
Description: The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
Study: NCT00432159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical TDR
Description: Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
Study: NCT02718001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EVOQUE Eos Mitral Valve Replacement System
Description: Replacement of the mitral valve through a transcatheter approach
Study: NCT00432159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical TDR
Description: Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical TDR
Description: Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF with plate
Description: Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACDF with plate
Description: Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
Study: NCT02643771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Mouth Scaling and Root Planing
Description: This procedure was performed as described by Quirynen et al. 2005 with some modifications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Full Mouth Scaling and Root Planing
Description: This procedure was performed as described by Quirynen et al. 2005 with some modifications
Study: NCT03344731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: Transcranial Magnetic Stimulation (TMS)
Study: NCT02743403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurodyn Portable activeTENS, IBRAMED®
Description: Randomization and secret Allocation active TENS (GI / n = 27)
Study: NCT02214381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet
Study: NCT02743403

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurodyn Portable activeTENS, IBRAMED®
Description: Randomization and secret Allocation active TENS (GI / n = 27)
Study: NCT02214381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study: NCT01304524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX 3100
Description: 1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
Study: NCT04006795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serum
Description: Participants will be topically applied adhesive patch containing developmental serum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lotion
Description: Participants will be topically applied adhesive patch containing developmental lotion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream
Description: Participants will be topically applied adhesive patch containing developmental cream
Study: NCT02743403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurodyn Portable placeboTENS, IBRAMED®
Description: Randomization and secret Allocation placebo TENS (GII / n = 27)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neurodyn Portable placeboTENS, IBRAMED®
Description: Randomization and secret Allocation placebo TENS (GII / n = 27)
Study: NCT04006795

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will be topically applied adhesive patch containing normal saline
Study: NCT03064503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be performed to measure interstitial fibrosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Skin auto-fluorescence
Description: Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
Study: NCT03452111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nestorone + Testosterone Combination Gel
Description: The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel. About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume.
Study: NCT03224338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B\*5701 allele screening assessment.
Study: NCT04071080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorescein sodium
Description: Fluorescein sodium in 500mL Gatorade

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500mL Gatorade
Study: NCT02743403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxyderm S20-1C
Description: Randomization and secret Allocation control group (CG / n = 27).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Carboxyderm S20-1C
Description: Randomization and secret Allocation control group (CG / n = 27).
Study: NCT02775864

Intervention type: DRUG
Intervention: Antipsychotic
Description: New initiation of any antipsychotic medication

Intervention type: DRUG
Intervention: Antidepressant
Description: New initiation of any antidepressant medications

Intervention type: DRUG
Intervention: Benzodiazepine
Description: New initiation of any benzodiazepine

Intervention type: DRUG
Intervention: Mood stabilizer
Description: New initiation of lithium or any mood stabilizing anti-epileptic drug